Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 41,861 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the transaction, the director owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. This represents a 72.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Roivant Sciences Stock Down 1.8%

Shares of ROIV opened at $27.80 on Thursday. The company has a 50-day moving average price of $25.68 and a two-hundred day moving average price of $21.04. The stock has a market cap of $19.90 billion, a price-to-earnings ratio of -23.76 and a beta of 1.17. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $30.33.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. The Goldman Sachs Group upped their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Leerink Partners raised their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $28.81.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its stake in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its stake in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. boosted its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Roivant Sciences during the fourth quarter worth about $47,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.